Author

J. E. Pickett

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Pharmacology & Toxicology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Organism:human· 2 Organism:mouse· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

C. I. Wells· 3 shared W. J. Zuercher· 2 shared A. Basbaum· 1 shared A. Goenka· 1 shared A. U. Schirmer· 1 shared B. Erdogdu· 1 shared B. Hu· 1 shared B. J. Bender· 1 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 16 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

C. I. Wells

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Structure-Based Discovery of a NPFF1R Antagonist with Analgesic Activity

B. J. Bender, J. E. Pickett, J. Braz, H. J. Kang, S. Gahbauer, K. Bhardwaj, S. Rodriguez-Rosado, Y. Liu, M. Jain, A. Basbaum, B. L. Roth, B. K. Shoichet

This paper identifies a selective NPFF1R antagonist with analgesic properties, showing enhanced pain relief when combined with morphine and reduced side effects.

bioRxiv · Oct 25, 2023 · PreprintPharmacology & Toxicology

Temozolomide-induced guanine mutations create exploitable vulnerabilities of guanine-rich DNA and RNA regions in drug resistant gliomas

D. M. Tiek, B. Erdogdu, R. Razaghi, L. Jin, N. Sadowski, C. Alamillo-Ferrer, J. R. Hogg, B. R. Haddad, D. H. Drewry, C. I. Wells, J. E. Pickett, X. Song, A. Goenka, B. Hu, S. L. Goldlust, , R. B. Riggins

This study identifies guanine mutations in TMZ-resistant gliomas that disrupt G4 structures and splice sites, creating vulnerabilities targeted by G4 stabilizers and splicing inhibitors.

bioRxiv · Nov 21, 2021Cancer Biology

Non-canonical role of Hippo tumor suppressor serine/threonine kinase 3 STK3 in prostate cancer

A. U. Schirmer, L. M. Driver, M. T. Zhao, C. I. Wells, J. E. Pickett, S. N. O'Bryne, B. J. Eduful, X. Yang, L. Howard, S. You, G. R. Devi, J. Digiovanni, S. F. Freedland, J.-T. A. Chi, D. Drewry, E. Macias

This study shows that STK3, typically a tumor suppressor, promotes prostate cancer growth and identifies STK3 inhibitors with therapeutic potential.

bioRxiv · Feb 21, 2021Cancer Biology

Development of SGC-GAK-1 as an orally active in vivo probe for cyclin G associated kinase through cytochrome P450 inhibition

C. R. M. Asquith, J. M. Bennett, L. Su, T. Latinen, J. M. Elkins, J. E. Pickett, C. I. Wells, Z. Li, T. M. Willson, W. J. Zuercher

The paper develops SGC-GAK-1 as an orally active in vivo probe for GAK by using cytochrome P450 inhibition to improve its metabolic stability and plasma exposure.

bioRxiv · May 7, 2019 · PreprintPharmacology & Toxicology